Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
WEBJul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
FDA approves pembrolizumab with chemotherapy for …
WEB4 days ago · Patients were randomized (1:1) to receive either pembrolizumab for up to 2 years in combination with pemetrexed and platinum-based chemotherapy for up to 6 cycles (n=222) or pemetrexed and ...
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of ... - Merck
WEBJul 27, 2021 · FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery. Save. July 27, 2021 6:30 am ET.
Pembrolizumab + Chemo Aids Early-Stage Triple-Negative Breast …
WEB2 days ago · THURSDAY, Sept. 19, 2024 (HealthDay News) -- For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a significant improvement in overall survival compared with neoadjuvant chemotherapy alone, according to a study published online Sept. 15 in the New England Journal of Medicine to coincide with the ...
FDA approves pembrolizumab for high-risk early-stage triple …
WEBOn July 26, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy...
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB...
FDA Approves Pembrolizumab with Chemotherapy for …
WEB2 days ago · On 17 September 2024, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). Efficacy was investigated in KEYNOTE-483 (NCT02784171), a randomised, open-label study in patients ...
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before …
WEB5 days ago · RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first-time presentation of overall survival (OS) results from the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single ...
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell …
WEBJun 3, 2023 · Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major...
Pembrolizumab improves outcomes in high-risk bladder cancer
WEB5 days ago · NCI Press Office. 240-760-6600. Adjuvant pembrolizumab helps people with muscle-invasive bladder cancer remain cancer-free longer than observation alone. Credit: Terese Winslow/National Cancer Institute. Results from a large clinical trial show that treatment with an immunotherapy drug may nearly …